Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

New CMO and Takeda alum Palmer adds to Ascletis’ push into NASH

By Jeff Cranmer, Executive Editor
November 30, 2020 3:42 AM UTC
Updated on Dec 1, 2020 at 2:47 AM UTC

Ascletis is looking to Takeda veteran Melissa Palmer to move its pipeline of in-licensed and homegrown NASH programs forward.

Ascletis Pharma Inc. (HKEX:1672) announced Monday that Palmer, the former head of liver disease clinical development at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), will join the infectious disease company’s dedicated non-alcoholic steatohepatitis (NASH) unit, Gannex, as its first CMO...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Ascletis Pharmaceuticals Co. Ltd.